In this phase III trial, T-DM1 (for 14 cycles) was compared with trastuzumab for patients with HER2-positive early breast cancer who were found to have residual invasive disease at surgery after neoadjuvant therapy including a trastuzumab and a taxane (with or without anthracycline). The gene discussed is ERBB2; the disease is breast cancer.